pilot study of elemene in treating patients with refractory glioblastoma

Conditions: Refractory Glioblastoma

Summary: this is a pilot phase i study to evaluate the safety and efficacy on elemene injectable emulsion in treating patients with glioblastoma. elemene, isolated from the chinese medicinal herb curcuma wenyujin, was shown to exhibit antitumor activity in human and murine tumor cells in vitro and in vivo.elemene injectable emulsion against malignant tumors was low. therefore, the effect of elemene injectable emulsion being used in clinical settings needs to be confirmed by further rcts.

background * elemene, isolated from the chinese medicinal herb curcuma wenyujin, was shown to exhibit antitumor activity in human and murine tumor cells in vitro and in vivo * the study shows that the methodological quality of rcts of elemene injectable emulsion against malignant tumors was low. therefore, the effect of elemene injectable emulsion being used in clinical settings needs to be confirmed by further rcts objectives * to evaluate the safety of elemene injectable emulsion to treat refractory glioblastoma with tmz * to evaluate the efficacy of elemene injectable emulsion to treat refractory glioblastoma with tmz design this clinical trail is a randomized controlled trial.in control group,patients will receive tmz-chemotherapy.in experimental group,patients will receive elemene injectable emulsion and tmz-chemotherapy at the same time.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years; male or female. 2. relapsed/refractory disease confirmed by radiographic evidence after standard therapy. 3. kps ≥ 60 4. ≥ 8 weeks after completion of front-line radiation therapy 5. ≥ 6 weeks after completion of nitrourea chemotherapy 6. ≥ 14 days after completion of temozolomide or other chemotherapy 7. 2 weeks of wash-out time after completion of targeted therapy with related adverse events (ae) on baseline 8. white blood cell count (wbc) ≥ 3.0 x 109/l; peripheral blood lymphocyte (pbl) ≥ 25%. 9. echocardiographic assessment of left ventricular ejection fraction (lvef) ≥ 40% within 1 month of enrollment. 10. patients must be able to understand the investigational nature of the study and provide informed consent. exclusion criteria: 1. those who are allergic constitution, or have contraindications to ct and mri1 contrast agents. 2. those who plan to receive any other anti-tumor treatment during the trial. 3. combined with serious primary diseases of cardiovascular, liver and kidney, and liver function (alt, ast, y-gt) exceeding 1.5 times of the upper limit: bun or cr exceeding 1.5 times of the upper limit of normal value. 4. patients with other malignant tumors. 5. those with active infections, etc. 6. suspected or confirmed a history of alcohol and drug abuse. 7. psychiatric illness, intellectual and language disabilities that compromise the informed consent process, at the discretion of the investigator. 8. women who are pregnant or nursing. 9. women of childbearing age who refuse to contraception. 10. active participation in another clinical treatment trials. 11. according to the judgment of the investigator, other conditions that the plan cannot be followed.